Viewing Study NCT03675893


Ignite Creation Date: 2025-12-25 @ 1:14 AM
Ignite Modification Date: 2026-01-04 @ 12:23 AM
Study NCT ID: NCT03675893
Status: RECRUITING
Last Update Posted: 2025-06-15
First Post: 2018-09-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Sponsor: Dana-Farber Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module